Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

Despite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly ...

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

Two bills aim to close gaps and ensure equitable access by requiring private health insurance coverage of FDA-approved Alzheimer’s treatments.

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

The Ironman Triathlon is a grueling 140 miles, which includes a 2.4-mile swim, a 112-mile bike ride and a 26.2-mile marathon ...

It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...

Opens in a new tab or window Donanemab raised the risk of amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients ... which also include lecanemab (Leqembi). The donanemab secondary ...